Pharmacodynamics of immunosuppressive drugs

Current Opinion in Immunology

Volumn 12, Issue 5, 2000, Pages 557-562

  Dambrin, Camille ^a   Klupp, Jochen ^a   Morris, Randall E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; BINDING PROTEIN; CALCINEURIN; CELL ADHESION MOLECULE; CYCLOSPORIN; CYTOKINE; DIHYDROOROTATE DEHYDROGENASE; DNA; FK 779; GROWTH FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; LEFLUNOMIDE; MALONONITRILAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATASE; PREDNISOLONE; RAPAMYCIN; S6 KINASE; TACROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GRAFT REJECTION; HUMAN; NONHUMAN; PHARMACODYNAMICS; REVIEW;

EID: 0033811781     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00138-2     Document Type: Review

References (53)

1. The monitoring of immunosuppressive drugs: A pharmacodynamic approach
2. Therapeutic drug monitoring of immunosuppressant drugs
3. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
4. Newer immunosuppressive drugs: A review
5. Immunosuppressive drugs: Non-biologics
6. Whole-blood lymphocyte cultures
7. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation
8. New approach in drug development: Whole blood pharmacodynamic assays reflect biological activities of tacrolimus
9. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation
10. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
11. Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium
12. The temporal profile of calcineurin inhibition by cyclosporine in vivo
13. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by flow cytometry, according to Immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients
14. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis
15. Quantitation of immunosuppression by FK506 using flow cytometric analysis of IL-2 and INFγ inhibition in peripheral blood T cells
16. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes
17. Prolongation of rat heart allograft survival by RS-61443
18. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
19. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo-controlled trial
20. Pharmacodynamic assessment of mycophenolic acid in a canine model
21. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model
22. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
23. Pharmacodynamic monitoring of mycophenolate mofetil by measurement of IMPDH acitivity
24. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil
25. Pharmacodynamics of immunosuppression by mycophenolic acid: Inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics
26. Pharmacodynamics of mycophenolic acid in a rat heart allograft model: Correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology
27. Pharmacodymnamics (PD) of mycophenolate mofetil (MMF) after heart transplantation identity new mechanism of action and correlate with severity of rejection
28. Mycophenolate mophetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN to LEW heterotopic heart transplant model
29. Novel mechanisms of action of mycophenolic acid (MPA): Inhibition of expression of CD28 and CD154 costimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF)
30. Mycophenolate mofetil: A report of the consensus panel
31. Identification of a new pharmacologic action for an old compound
32. Rapamycin for immunosuppression in organ allografting
33. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action and immunosuppressive effect result from blockade of signal transduction and inhibition of cell cycle progression
34. P70 S6 kinase assay: A pharmacodynamic monitoring strategy for rapamycin; assay development
35. Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays
36. Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats
37. Flow cytometry detection of intracytoplasmic cytokines after Neoral or sirolimus intake is an informative tool for monitoring in vivo immunosuppressive efficacy in renal transplant recipients
38. Immunopharmacological profile of a novel isoxazol derivative HWA 486 with potential antirheumatic activity. Disease modifying action on adjuvant arthritis of the rat
39. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group
40. Leflunomide and malononitrilamides
41. Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis
42. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
43. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
44. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound
45. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides
46. Malononitrilamides inhibit T- and B-cell responsiveness in different species
47. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay
48. Diagnosis and treatment of inborn errors of purine and pyrimidine metabolism: An overview
49. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
50. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis
51. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans
52. Monitoring of pharmacodynamic (PD), but not pharmacokinetics (PK), differentiate the relative immunosuppressive potencies of leflunomide and its malononitrilamide (MNA) analogs
53. Inhibition of dihydroorotate dehydrogenase (DHODH) is the molecular mechanism of immunosuppression by the malononitrilamides (MNAs) in vivo